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Abstract: Alzheimer’s disease (AD) is an aging-related multi-factorial disorder to which metabolic 
factors contribute at what has canonically been considered a centrally mediated process. Although the 
exact underlying mechanisms are still unknown, obesity is recognized as a risk factor for AD and the 
condition of insulin resistance seems to be the link between the two pathologies. Using mice with high 
fat diet (HFD) obesity we dissected the molecular mechanisms shared by the two disorders. Brains of 
HFD fed mice showed elevated levels of APP and Aβ40/Aβ42 together with BACE, GSK3β and Tau proteins involved in 
APP processing and Aβ accumulation. Immunofluorescence, Thioflavin T staining experiments, confirmed increased Aβ 
generation, deposition in insoluble fraction and plaques formation in both the hippocampus and the cerebral cortex of 
HFD mice. Presence of Aβ40 and Aβ42 in the insoluble fraction was also shown by ELISA assay. Brain insulin resistance 
was demonstrated by reduced presence of insulin receptor (IRs) and defects in Akt-Foxo3a insulin signaling. We found 
reduced levels of phospho-Akt and increased levels of Foxo3a in the nuclei of neurons where proapototic genes were acti-
vated. Dysregulation of different genes related to insulin resistance, especially those involved in inflammation and adipo-
cytokines synthesis were analyzed by Profiler PCR array. Further, HFD induced oxidative stress, mitochondrial dysfunc-
tion and dynamics as demonstrated by expression of biomarkers involved in these processes. Here, we provide evidence 
that obesity and AD markers besides insulin resistance are associated with inflammation, adipokine dyshomeostasis, oxi-
dative stress and mitochondrial dysfunction, all mechanisms leading to neurodegeneration.  
Keywords: Adipokines, Alzheimer’s disease, gene expression, inflammation, insulin resistance, mitochondrial dysfunction, 
obesity. 
1. INTRODUCTION 
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disease that is mainly diagnosed by its clinical fea-
tures including progressive impairment of cognitive func-
tion, orientation, and motor activity, language disturbance, 
difficulty in recognizing or identifying objects and persons. 
Histopathological hallmarks of AD are the so-called senile 
plaques and neurofibrillary tangles obtained respectively by 
deposition of the aggregated β amyloid peptide (Aβ) and 
hyperphosphorylated Tau protein [1]. Aβ peptide derives 
from the sequential proteolytic cleavage of amyloid precur-
sor protein (APP) by β-site APP cleaving enzyme 1 
(BACE1) and γ−secretase, a multi-subunit protease complex 
comprised of proteins such as presenilin 1 or 2 (PS1, PS2) 
[1, 2]. 
The prevalence of AD is progressively increasing in the 
world population. Thirty-five million people are now consid- 
ered to be affected by AD and this number is expected to 
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double in the next few decades [3]. In parallel, an increase in 
incidence of obesity has been observed during the last years 
[4]. In countries with a developed status the obesity is cur-
rently the most common nutritional disorder, with serious 
health-impairing consequences, not the least of which cogni-
tive impairment [5]. In fact, some studies have reported that 
obesity is associated with reduced cognitive performance in 
humans [6, 7] as well as decreased brain volumes [8] and it 
is correlated with an increased probability of developing 
cognitive decline, including AD [9, 10]. According to Rot-
terdam studies, patients with obesity or other metabolic dis-
eases, such as Type 2 Diabetes (T2D), have almost a two-
fold greatest risk of developing AD [11].  
Unfortunately, to date the precise mechanisms associat-
ing obesity to AD are unclear. In particular, specific molecu-
lar mechanism/s linking the pathophysiology of obesity to 
the brain alterations of AD remains poorly known. Different 
factors have been implicated, such as increased levels of 
APP in adipose tissue [12] and Aβ in plasma of obese indi-
viduals [13] and the presence of insulin resistance [5]. In-
deed, numerous studies have indicated obesity as a factor 
which predisposes people to T2D and induces insulin resis-
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amongst people who are obese. Insulin has a significant role 
in modulation of synaptic plasticity and learning memory 
[15, 16]. High concentrations of insulin are present in brain 
extracts and insulin receptors (IR) are highly expressed in 
brain regions that support memory formation, indicating that 
insulin may have a role in maintaining regular cognitive 
function [16]. Alterations in the concentration of insulin and 
insulin receptors in the brain have been reported in AD, lead-
ing some to consider AD as brain diabetes or ‘‘Type 3 diabe-
tes’’ [17]. As such, irregularities in the insulin signaling 
pathway may contribute to impairment of memory function, 
comparable to those observed in patients with AD [18]. 
Moreover, animal and clinical studies have shown that intra-
nasal administration of insulin improves cognitive behavior 
in mice, perhaps by modulating neuronal communication 
within the brain [19, 20].  
A high fat diet (HFD) is one of main factors that can 
promote obesity and previous studies have shown that such a 
diet can produce learning and memory impairments in ro-
dents [21-24]. HFD was previously shown to induce a re-
markable brain insulin resistance as well as spatial memory 
impairment in a normal mouse or a transgenic model of AD 
[25]. However, whether the state of hyperinsulinemia in ro-
dents can induce alterations in the central nervous system 
(CNS) remains controversial and observations seem to de-
pend on the experimental approach to induce hyperinsuline-
mia and the specific tests performed [26-29]. Therefore this 
study was undertaken in an attempt to understand the under-
lying mechanisms by which adipose tissue might influence 
cerebral structures related to learning and memory. With this 
view, we explored different points of molecular alterations 
present in the brains of C57BL6 mice fed HFD an animal 
model of diet-induced obesity and insulin resistance. In par-
ticular, we analyzed the effect of high fat diet intervention on 
brain metabolism, redox balance and mitochondrial homeo-
stasis. In addition, the gene expression changes involved in 
the brain insulin resistance were analyzed.  
2. MATERIAL AND METHODS  
2.1. Mice 
The experimental procedures employed in the present 
study were in accordance with the Italian D.L. no. 116 of 27 
January 1992 and subsequent variations and the recommen-
dations of the European Economic Community 
(86/609/ECC). The studies were approved by Ministero della 
Sanita` (Rome, Italy). Male C57BL/6J (B6) mice, purchased 
from Harlan Laboratories (San Pietro al Natisone Udine, 
Italy) at 4 weeks of age, were housed under standard condi-
tions of light (12h light: 12h darkness cycle) and temperature 
(22–24°C), with free access to water and food. After accli-
matization (1 week), the animals were weighed and divided 
in two groups, which were fed a standard diet (STD) 
(4RF25, Mucedola, Milan, Italy), or fed for 23 weeks (7 
months) a high fat diet (HFD) (PF4051/D, Mucedola) con-
sisting of 23% protein, 38% carbohydrates, and 34% fat 
(60% caloric fat content), as previously described [30]. Ani-
mals were weighed and killed by cervical dislocation. The 
brains of age-matched animals were immediately exported, 
weighted and processed for subsequent analysis. 
2.2. Glucose, Insulin and Insulin Tolerance Tests 
Body weight, blood glucose and insulin levels were de-
termined before sacrifice. Briefly blood glucose levels were 
measured from nicked tails using a glucometer (GlucoMen 
LX meter, Menarini, Italy). Quantification of plasma insulin 
was carried out by mouse enzyme-linked immunosorbent 
assay (Alpco Diagnostics, Salem, NH USA) according to the 
manufacturer’s instructions. Insulin tolerance test (ITT) was 
carried out in mice fasted for 6 h with free access to water. 
Mice were given an i.p. injection of insulin (1.2 U/kg body 
weight) (Insuman Rapid, Sanofi Aventis, Italy) in 0.9% sa-
line and plasma glucose was measured at different interval 
up to 120 min (0, 15, 30, 60, 90, 120).  
2.3. Total Protein Extraction and Western Blotting 
Brain of mice were homogenized in RIPA buffer (20 mM 
Tris, pH 7.4, 150 mM NaCl, 1 mM Na3VO4, 10 mM NaF, 
1mM EDTA, 1 mM EGTA, 0.2 mM phenylmethylsulfonyl 
fluoride, 1% Triton, 0.1%SDS, and 0.5% deoxycholate) with 
protease inhibitors (Amersham) and phosphatase inhibitor 
cocktail II and III (SIGMA). To remove insoluble material 
tissue lysates were sonicated and centrifuged (14,000 rpm, at 
4°C, for 30 min). Proteins (50 µg) were resolved by 10% 
SDS-PAGE gel and transferred onto nitrocellulose filters for 
Western blotting using anti-APP (1:1000), anti-Presenilin1 
(1:1000), anti-p-ERK (1:1000), anti-heme-Oxygenase 
(1:500), anti-SOD2 (1:500), anti-Bad-2 (1:500), anti-
VDAC1 (1:500), and anti-BACE1 (1:1000), anti-phospho-
GSK-3β (Tyr216) (1:500) purchased from Santa Cruz, anti-
IR (1:500), anti-GSK3α/β (1:1000), anti-i-NOS (1:500), anti-
HSP60 (1:500), anti-FoxO3a (1:1000) and anti-phospho-
Foxo3a (Ser253) (1:500) purchased from Cell Signaling, 
anti-AKT (1:1000), anti-phospho-Akt (Ser473) (1:500) pur-
chased from Invitrogen, anti-phospho-Tau (Thr205) (1:200) 
purchased from Abcam, anti-β-actin (1:5000) purchased 
from Sigma. Secondary antibodies conjugated to horseradish 
peroxidase (1:2000) purchased from Cell Signaling were 
detected using the NOVEX® ECL HRP chemiluminescence 
kit (Cat. n° WP20005, Invitrogen) according to the manufac-
turer’s instructions. In some instances, antibodies were 
stripped from blots with Restore Western Blot Stripping 
Buffer (Thermo Scientific) for 10 minutes at room tempera-
ture, for antibody reprobing. Band intensities were analyzed 
with a gel documentation system (BioRad), expression was 
normalized with β-actin expression. The protein levels were 
expressed as densitometry and percentage of controls. 
2.4. Preparation of Soluble and Insoluble Brain Fractions 
Brain tissues were homogenated in ∼10 ml buffer/gram 
tissue in low salt buffer (LSB) (10 mM Tris, pH 7.5, 5 mM 
EDTA, 1 mM DTT, 10% (wt/vol) sucrose, Sigma protease 
inhibitor cocktail II and III). After centrifugation at 14,000 
rpm for 30 min at 4°C, the supernatant was retained as solu-
ble fraction and the pellet was resuspended in a detergent 
buffer (LSB plus 1% sarkosyl, N-Lauroylsarcosine and 0.5M 
NaCl). After brief sonication and centrifugation at 14,000 
rpm for 50 min at room temperature, the supernatant was 
retained as detergent insoluble fraction. The soluble fraction 
and the detergent insoluble fraction were utilized for the 
ELISA assays. An enzyme-linked immunosorbent sandwich 
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assay (ELISA) (Invitrogen) was performed for quantitative 
detection of mouse β-Amyloid (1-40) and (1-42) in soluble 
and detergentin soluble brain fractions according to manu-
facturer’s instructions. 
2.5. Preparation of Cytoplasmic and Nuclear Protein Ex-
tracts  
Nuclear and cytoplasmic extracts were prepared using 
NE-PER Nuclear and Cytoplasmic Extraction Reagents kit 
(Cat. n° 78833, Thermo Scientific) according to the manu-
facturer’s instructions using buffers provided. 
2.6. Immunomorphological Analyses: Immunohistochem-
istry and Immunofluorescence  
For tissue preparation, brains from STD and HFD fed 
mice (n=3 per group) were harvested. The mice were sacri-
ficed by cervical dislocation; the brains were removed, 
weighted and fixed in 4% formalin for 24h. The brains were 
embedded in paraffin and sectioned coronally (5µm) using a 
microtome. Brain sections including the hippocampus and 
cerebral cortex were mounted on superfrost plus tissue slides 
(Menzel-Gläser, Menzel-Glaser, Braunschweig, Germany) 
and deparaffinized. The slides were immersed in 0.3% H2O2 
for 5 min to quench endogenous peroxidase activity, and 
treated with 10 mM, pH 6.0, 0.05% Tween 20 tri-sodium 
citrate at 95°C for 8 min for antigen retrieval. Subsequently, 
immunohistochemistry was performed as previously de-
scribed [31] using the Histostain-Plus IHC detection Kit 
(Histostain-plus Kit3rd Gen IHC Detection Kit, Life Tech-
nologies, Monza, Italy) according to the manufacturer’s in-
structions. The sections were incubated with anti-APP 
(1:200) purchased from Santa Cruz and 3–3-
diaminobenzidine (DAB chromogen solution, DAKO, Glos-
trup, Denmark) was used as developer chromogen. Nuclear 
counter staining was done using haematoxylin (DAKO). 
Appropriate positive and negative controls, were run concur-
rently. The slides were mounted with cover slips and images 
were taken with a Leica DM5000 upright microscope (Leica 
Microsystems, Heidelberg, Germany) at a magnification of 
20X. For immunofluorescence sections were stained using 
the same primary antibody against APP used for immunohis-
tochemistry (Santa Cruz, dilution 1:100) and with anti-IR 
(Cell Signaling, dilution 1:100) at 4°C overnight. After 
washing in PBS, the slides were incubated with anti-rabbit 
TRITC-conjugate and anti rabbit-FITC-coniugated secon-
dary antibodies (SIGMA). Nuclear staining was performed 
using Hoechst 33258 (5µg/mL). For Thioflavin T (ThT) 
staining the brain slides were incubated with a 70 µM work 
solution for 10 minutes. The samples were analyzed by using 
a DHL fluorescent microscope (Leica Microsystems, Hei-
delberg, Germany) at a magnification of 20X. Fluorescence 
intensity was measured using Leica QFluoro program. 
2.7. Quantitative Real-Time qPCR  
Total RNA was extracted using RNeasy Lipid Tissue 
Mini Kit (Qiagen). Two ng of RNA was used to synthesize 
the first strand cDNA using RT First-Strand kit (Qiagen). 
Synthesized cDNAs were amplified using RT2 SYBR 
Green/ROX qPCR Mastermix (Qiagen) and StepOne Real-
Time instrument (Applied Biosystem). Gene expression 
validation was performed using home-made sequence prim-
ers for human APP, Foxo3a, Bim, Fas-Ligand, P27 and β-
actin (Table 1) or using commercial sequence primers listed 
in Table 2 (SABiosciences). Gene expression was normal-
ized to β-actin. On the basis of the Ct value (threshold cycle-
the number of reaction cycles after which fluorescence ex-
ceeds the defined threshold) of the examined gene and of the 
internal control gene the relative expression level of RNA 
was calculated according to the 2-ΔΔCt approximation method. 
2.8. RT2 ProfilerPCR Array  
Mouse Insulin resistance (PAMM-156Z) focused path-
way arrays (Insulin Resistance PCR Array, SABiosciences) 
in 96-well plate format were used to assay gene expression 
changes. Samples were prepared from pooled RNA extracted 
from STD and HFD mouse brains. Samples were added to 
the reaction plates following the manufacturer’s instructions 
and and a StepOne Real-Time instrument (Applied Biosys-
tem) was used to perform the array. Analysis was performed 
using the spreadsheet provided by SABiosciences.  
2.9. Statistical Analysis  
The results are presented as mean ± SD. Statistical 
evaluation was conducted by two-way ANOVA, followed by 
Student’s t-test for analysis of significance. Results with a p-
value <0.05 were considered statistically significant, 
*P<0.05, **P<0.02. 
Table 1. Sequences of primers used for real-time PCR analysis. 
Gene Forward Reverse 
APP 5’-CTGACCACTCGACCAGGTTCT-3’ 5’-GTCGATAACCCCTCCCCCAGC-3’ 
FoxO3a 5’- TCTACGAGTGGATGGTGCGTT-3′ 5’-CGACTATGCAGTGACAGGTTGTG-3′ 
Bim 5’-AACCTTCTGATGTAAGTTCT-3’ 5’-GTGATTGCCTTCAGGATTAC-3’ 
Fas L 5'- CAAGTCCAACTCAAGGTCCATGCC-3' 5'-AGAGAGAGCTCAGATACGTTTGAC-3’ 
P27 5’- TGCGAGTGTCTAACGGGAG-3’ 5’- GTTTGACGTCTTCTGAGGCC-3’ 
β-actin 5'- GTGGGGCGCCCCAGGCACCA-3' 5'- CTCCTTAATGTCACGCACGATTTC-3' 
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3. RESULTS 
3.1. Effects of HFD on Body and Brain Weights 
In an effort to better understand the effect of high caloric 
diet on brain metabolism and risk of developing AD, 
C57BL6/J mice were fed with a high fat diet or a standard 
diet for seven months. Body and whole brain weights were 
measured (n=5 per group) at the time of sacrifice and the 
brain/body weight ratio was calculated. The HFD animals 
had a significantly higher weight, body weight relative to 
controls fed a standard diet. Moreover, the mean brain 
weights were lower in HFD than standard diet fed animals. 
However, the calculated mean brain/body weight ratio was 
significantly reduced in the HFD mice due to the combined 
effects of obesity and mild brain atrophy (Table 3). For the 
expression experiments we chose to utilize STD mice with a 
brain/body weight ratio > 0.01 (n=3 per group) and HFD 
mice with a brain/body weight ratio < 0.08 (n= 3 per group).  
3.2. AD Markers Increase in Brains from HFD Versus 
Control Fed Mice 
To examine whether HF feeding changed the expression 
levels of proteins with a well-established link to AD pathol-
ogy such as APP, BACE, PSN1, total and active GSK3β and 
phosphorylated Tau, a Western blot of proteins extracted 
from brains of HFD and standard diet fed animals was per-
formed (Fig. 1A,B). Brain extracts from HFD mice revealed 
a significant increase in expression of APP and its cleavage 
peptides Aβ40 and Aβ42 compared to control diet fed mice. In 
agreement with this, an increase of BACE, an enzyme re-
quired for processing of APP to produce its pathogenic 
cleavage product Aβ, was observed, whereas no significant 
change was observed for PSN1. A substantial increase of 
GSK3β a protein involved in multiple processes such as Tau 
hyper-phosphorylation and Aβ production and mitochondrial 
dysfunction, was also detected. Furthermore, activation of 
GSK3β corresponded to an increase in Tau phosphorylation. 
Accordingly with protein levels observed, expression of APP 
mRNA, analyzed by quantitative real-time PCR (qRT-PCR), 
was significantly increased in HFD mice (Fig. 1C). Further-
more, we visualized the presence of APP by immunofluores-
cence and immunohistochemistry experiments using coro-
nary brain sections in which the hippocampus and cerebral 
cortex, two regions damaged in AD, were visible (Fig. 
1D,E,F). We observed increased immunoreactivity of APP 
in both the hippocampus and cortex of HFD mice compared 
to controls and some Aβ deposits were detected, indicating 
an increase in APP processing and aggregation of Aβ. 
Moreover, staining with Thioflavin T, a dye used to visualize 
the presence or fibrilization of misfolded protein aggregates, 
or amyloid plaques, demonstrated the presence of insoluble 
Aβ aggregates (Fig. 1G). To confirm the presence of insolu-
ble Aβ aggregates or amyloid plaques we utilized an anionic 
detergent to obtain a soluble and insoluble fraction from 
STD and HFD brain tissue. Increased levels of Aβ40 and 
Aβ42 aggregates were detected by ELISA assay in the deter-
Table 2. List of genes and catalog number of commercial primers used for real-time PCR analysis. 
Symbol Description RT2 Catalog 
Ifng Interferon gamma PPM03121A 
Pck1 Phosphoenolpyruvate carboxykinase 1, cytosolic PPM05113F 
Cd3e CD3 antigen, epsilon polypeptide PPM04598A 
Cxcr3 Chemokine (C-X-C motif) receptor 3 PPM03145F 
Adipoq Adiponectin, C1Q and collagen domain containing PPM05260A 
Retn Resistin PPM05076A 
Pdx1 Pancreatic and duodenal homeobox 1 PPM04509D 
Ccr4 Chemokine (C-C motif) receptor 4 PPM03147A 
Lep Leptin PPM03504B 
Actb Actin, beta PPM02945B 
 
Table 3. Brain weights from C57BL/6J (n =5 each) maintained with standard (STD) or high fat diet (HFD) for 7 months. Data 
represent means ± S.D. 
Diet n Age (months) Body (±sd) p-value Brain (±sd) p-value Weight ratio 
brain/body p-value 
STD 5 7 27.6 g ± 0.9 0.33 g ± 0.06 0.0123 ± 0.002 
HFD 5 7 36.4 ± 2 < 0.005 0.27 ± 0.04 < 0.05 0.0077 ± 0.001 < 0.05 
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gent insoluble fraction with respect to soluble fraction (Fig. 
1H).  
3.3. High Fat Diet Fed Mice Show Insulin Resistance 
The HFD mice had significantly higher fasting plasma 
glucose levels (Fig. 2A) and increased insulin (11.8 ± 3.5 
ng/ml, n=5 P<0.01) compared to standard diet (0.8 ± 0.2 
ng/ml; n=5) fed animals. Moreover, the ITT showed that in 
HFD mice the levels of blood glucose after intraperitoneal 
exogenous administration of insulin decreased less in com-
parison to standard diet fed animals (Fig. 2A), suggesting the 
presence of insulin resistance. This is also illustrated by the 
measurement of the glucose area under the curve (AUC) 
(Fig. 2B). Insulin receptors were present on neurons in the 
brain and their reduced presence and activity was detectable 
in insulin resistance. Western blotting analysis revealed that 
brain levels of insulin receptor (IR) were decreased relative 
to controls (Fig. 2C,D), confirming cerebral insulin resis-
tance. Furthermore, immunofluorescence with anti-IR 
showed a reduced presence of these receptors in hippocam-
pus from HFD fed mice compared to controls, confirming 
the metabolic data (Fig. 2E,F).  
 
Fig. (1). Brain of diet induced obesity mice accumulates Aβ versus standard diet mice. A) Western blot of protein extracted from brain 
lysates of STD or HFD fed mice were incubated with anti-APP, presenilin 1 (PS1), BACE, GSK3β, phospho-GSK3β, phospho-Tau and β-
Actin (loading control) antibodies. B) Quantification of immunoreactivity was performed using densitometric analysis. C) Effect of HFD on 
APP transcript levels determined by quantitative real-time PCR. *P < 0.05 versus control group. D,E) Immunofluorescence and immunohis-
tochemistry of hippocampal (CA3 area) and cerebral cortex sections (CTX area) of STD or HFD fed mice stained using anti-APP antibody. 
The outlined area in E are enlarged to the right to show the clearly stained plaque. F) Histograms represent the fluorescence intensity of APP 
in hippocampal and cortex sections of STD and HFD fed mice. G) ThT staining of Aβ aggregates on cerebral cortex section. Nuclei were 
stained with Hoechst 33258 and merged images with ThT staining are shown. Arrows indicate the fragmented nuclei of the cells trapped in 
the plaque, in the enlarged figure on the right. Representative images from 3 animals per condition are shown. Bar 20 µm. H) Aβ40 and Aβ42 
quantification by ELISA in the soluble and detergent insoluble fractions of brain homogenates from STD and HFD fed mice. 
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Fig. (2). HFD induces insulin resistance. A) Plasma glucose concentrations during insulin tolerance test (ITT) B) AUC for blood glucose 
concentrations during ITT. Data are mean values ± SD (n=5 mice/group). *p ≤ 0.05. C) Western blot of brain lysates from STD and HFD fed 
mice incubated with anti-Insulin receptor (IR) and β-Actin (loading control) antibodies. D) Quantification of immunoreactivity was per-
formed using densitometric analysis. E) Immunofluorescence of hippocampal and cerebral cortex sections of STD or HFD fed mice stained 
using anti-Insulin receptor (Anti-IR). The outlined areas are enlarged in the squares. F) Histograms represent the fluorescence intensity of IR 
in hippocampal and cortex sections of STD and HFD fed mice. Representative images from 3 animals per condition are shown. Bar 20 µm. 
 
3.4. High Fat Diet Feeding Affects Insulin Signaling  
To assess whether reduced IR presence compromises in-
sulin signaling activation, a Western blot of total proteins 
extracted from brains of HFD and standard diet fed mice was 
incubated with antibodies against both the total and phos-
phorylated forms of Akt and Foxo3a. Decrease in Akt, 
posho-Akt and posho-Foxo3a levels and increase of Foxo3a 
were observed in HFD mice, indicating that the insulin sig-
naling was affected (Fig. 3A,C). Furthermore, we investi-
gated about the subcellular localization of activated or un-
activated forms of Akt and Foxo3a. In the nuclei of HFD 
mice, we observed a decrease in both Akt and phospho-Akt 
levels and a significant increase of Foxo3a (Fig. 3B,D,E). In 
contrast, we found an increase in both phospho-Akt and 
Foxo3a and a decrease of phospho-Foxo3a in the cytoplasm. 
Moreover, by using quantitative Real Time PCR we con-
firmed that in the nuclei Foxo3a activates the expression of 
apoptotic genes such as FasL, Bim and p27. HFD fed mice 
showed an increase of mRNA levels of both Foxo3a and 
Bim, Fas-L and p27, compared to control mice (Fig. 3F). 
Our results, as schematically shown in (Fig. 3G), indicate 
that in STD condition phosphorylated Akt promotes Foxo3a 
export from the nucleus to the cytoplasm inhibiting its tran-
scriptional activity. In contrast, in HFD condition, a decrease 
in phospho-Akt reduces Foxo3a phosphorylation and pro-
motes its translocation to the nucleus where it activates tran-
scription of its target genes (Fig. 3G). 
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Fig. (3). HFD affects Akt/Foxo3a pathway. A) Western blot of brain lysates from STD and HFD fed mice incubated with anti-Akt, phospho-
Akt (p-Akt), Foxo3a, phospho-Foxo3a (p-Foxo3a) and β-Actin (loading control) antibodies. B) Western blot of brain lysates from STD and 
HFD fed mice and subjected to subcellular fractionation in cytoplasmic (C) and nuclear (N) fractions and incubated with anti-Akt, phospho-
Akt (p-Akt), Foxo3a, phospho-Foxo3a (p-Foxo3a), Lamin B (nuclear loading control) and β-Actin (cytoplasmic loading control) antibodies. 
C,D,E) Quantification of immunoreactivity was performed using densitometric analysis. F) Effect of HFD on Foxo3a, Bim, FasL, P27 tran-
script levels determined by quantitative real-time PCR. n= 3 per group. *P < 0.05,**P < 0.02 versus control group. G) Schematic representa-
tion of p27, Bim and FasL gene activation after high fat diet induced Foxo3a nuclear translocation.  
 
3.5. HFD Affects Expression of Resistance Insulin Re-
lated Genes 
To assess the expression changes in genes involved in in-
sulin resistance in the brain we utilized a Profiler PCR array. 
Of the 84 genes, most of them were significantly differen-
tially expressed. These genes and the relative fold changes 
respect to the control are listed in Supplementary file 1 (Fig. 
S1). Among these, twelve were up- or down-regulated by 
more than 2 fold in HFD fed mice compared to the control 
(Fig. 4A). In addition, we validated the expression of some 
of the most highly expressed genes that were associated with 
inflammation (Interferon γ, CD3 antigen, Chemokine Recep-
tor 3, Chemokine receptor 4), adipokine signaling pathway 
(Adiponectin, Resistin, Leptin), and metabolism (Phosphoe-
nolpyruvate carboxykinase, Pancreatic and duodenal ho-
meobox 1), by quantitative real-time PCR (Fig. 4B,C). As 
shown, the observed changes were always of the same order 
of magnitude as those obtained by PCR Arrays.  
3.6. HFD Triggers Oxidative Stress and Mitochondrial 
Dysfunction  
To evaluate whether there was a condition of oxidative 
stress in the brain of HFD fed mice, protein markers of stress 
such as phospho-ERK (p-ERK), inducible nitric oxide syn-
thase (i-NOS), and antioxidant proteins such as superoxide 
dismutase 2 (SOD-2) and heme-oxigenase (H-Oxy), were 
analyzed by Western blotting. We found that the levels of p-
ERK and i-NOS were significantly increased, whereas the
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Fig. (4). PCR Array analysis of insulin resistance related genes. Brains from STD and HFD fed mice were used to prepare the mRNA for the 
PCR Array analysis. A) Scatter Plot of relative expression levels for each gene in the two samples (HFD vs STD). The figure shows a log 
transformation plot of the relative expression level of each gene (2-ΔΔCt) between STD mouse (x-axis) and HFD mouse (y-axis). The gray lines 
indicate a two-fold change in gene expression threshold. B) Table of quantitative real time PCR analysis (± SD) of the chosen genes. C) His-
togram of selected genes with a greater than 2-fold change in expression chosen to validate PCR Array. n= 3 per group. 
 
levels of SOD-2 and H-Oxy were decreased, indicating that a 
condition of oxidative stress was present (Fig. 5A,B). Simi-
larly, we determined alterations of some proteins that are 
markers of mitochondrial dysfunction. By Western blotting 
in brain homogenates from HFD or STD fed mice we de-
tected an increase of the levels of Bad-2 and voltage-
dependent anion channel (VDAC), mitochondrial matrix 
proteins, and a decrease of the levels of HSP60 indicating a 
condition of mitochondrial dysfunction (Fig. 6A,B). This 
condition was confirmed by analysis of fission and fusion 
markers, mechanism involved in mitochondrial dynamics. 
By Real Time PCR an increase in mRNA levels of Drp1 and 
Fis1 and a decrease in mRNA levels of OPA1 and Mfn1, 
compared to control mice was revealed (Fig. 6C), indicating 
that mitochondrial dynamics were perturbed in HFD fed 
mice. 
4. DISCUSSION 
Obesity is often associated with the consumption of a diet 
high in saturated fats, and several clinical/epidemiological 
studies have suggested this metabolic disease as a risk factor 
for the development of AD in later life [32, 33]. There is 
growing evidence to support the contribution of metabolic 
factors to this pathology, which have previously been con-
sidered limited to the central nervous system. However, the 
molecular mechanisms underlying this comorbidity, and the 
influence of high fat diet on cerebral structures, have not 
been well established. By use of a diet-induced obesity 
model, some of the molecules and pathogenic mechanisms 
shared by AD and this metabolic disorder were identified. 
Increased body weight and reduced cerebral weight was 
found in HFD mice. Loss in brain mass and volume is a fea-
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Fig. (5). Stress related proteins are modulated in high fat compared to standard diet fed mice. A) Western blot of protein brain lysates from 
STD and HFD fed mice was incubated with anti-phospho-ERK (p-ERK), i-NOS, H-Oxy, SOD2 antibodies.Uniformity of gel loading was 
confirmed with β-Actin as standard. B) Quantification of immunoreactivity was performed using densitometric analysis. n= 3 per group. *P < 
0.05, **P < 0.02 versus control group. 
 
 
Fig. (6). HFD impairs mitochondrial dynamics and induces mitochondrial dysfunction. A) Western blot of brain tissue lysates from STD and 
HFD fed mice probed with specific antibodies against Bad-2, VDAC, HSP60 mitochondrial proteins and β-Actin (general loading control). 
Arrow indicates bands of interest being present no specific bands. B) Quantification of immunoreactivity was performed using densitometric 
analysis. C) Effect of high fat versus standard diet on Fis1, Drp1, Opa and Mnf1 transcript levels determined by quantitative real-time PCR. 
n= 3 per group. *P < 0.05, **P < 0.02 versus control group. 
 
ture of AD and neuroimaging studies have indicated that  
disturbances in insulin metabolism, such as insulin resistance  
in obesity, T2D and AD, are linked to significant reduction  
of grey matter volume [34]. Moreover, studies using differ- 
ent diet compositions have demonstrated as high fat diet  
modulates levels of solubilized Aβ together with brain mass,  
density and volume [35]. Consistent with this result, we  
found that APP and certain proteins related to APP process- 
ing, including BACE1, are up-regulated in the brain of HDF  
fed mice. The increased presence of these proteins was  
associated with the increased production of Aβ40 and Aβ42.  
This explains the presence of insoluble Aβ fibrillar aggre- 
gates and amyloid plaques in hippocampal and cerebral cor- 
tex HFD brain sections, suggesting that neuronal network  
activity could be disturbed. Moreover, we found that acti- 
vated GSK3β had induced Tau phosphorylation, a step nec- 
essary for its aggregation in the form of paired helical fila- 
ments and neurofibrillary tangles is a hallmark, with amyloid  
plaques, of AD.  
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There is evidence that elevated APP levels are present 
both in brain and adipose tissue of HFD fed animals support-
ing the hypothesis that APP expression could be coordinately 
regulated between brain and fat tissue [36]. Furthermore, a 
study, using diet-induced insulin resistance in Tg2576 mouse 
model of AD, has demonstrated that insulin resistance pro-
moted an increase of Aβ peptide levels and early deposits, 
indicating that manipulation of diet could be a risk for AD 
[37]. Hence, monitoring of APP expression and processing 
in peripheral tissues could provide a checkpoint both for AD 
and obesity development and progression. Increase of APP 
gene expression may be correlated with insulin resistance 
and pro-inflammatory and adipocytokine gene expression 
[38, 39]. Insulin resistance, defined as a lower than expected 
response to a given dose of insulin, is a pathological condi-
tion characteristic of metabolic disorders as T2D, obesity 
and pathology related to aging [36]. Systemic insulin resis-
tance refers to the state in which high levels of blood insulin 
(hyperinsulinemia) are associated with hyperglycemia. We 
found that peripheral and central insulin resistance coexists 
in HFD fed mice. In fact, HFD fed animals showed high 
fasting plasma glucose levels, increased insulin and reduced 
sensitivity to exogenous insulin, suggesting a state of periph-
eral insulin resistance, as previously shown [40]. At the mo-
lecular level, insulin resistance corresponds to a reduced 
number of IRs and impairment in insulin signaling, with re-
duced activation of specific pathways involved in metabo-
lism and growth. High levels of IRs are present in healthy 
hippocampus, in contrast to the reduced levels that have been 
reported in patients with AD [17, 38]. In addition, studies 
using cultured neurons have demonstrated that IRs are redis-
tributed or decreased in number under Aβ stimulation [41-
43]. Our finding indicates that in the brains of HFD fed 
mice, the levels of IR are reduced, leading to compromised-
insulin signaling, as demonstrated by the analysis of Akt and 
Foxo3a expression and activation. When HFD is chronically 
ingested, Akt is down phosphorylated and Foxo3a translo-
cates from the cytoplasm to the nucleus where it activates its 
proapototic target genes. Thus, impairment of insulin signal-
ing induced by HFD can lead to neurodegeneration. Simi-
larly, caloric restriction mediates, in TG2576 mice, activa-
tion of the insulin signaling pathway, leading to phosphory-
lation and exclusion of Foxo3a from the nucleus, and pre-
vention of AD [44]. Furthermore, we cannot exclude that the 
consumption of a high fat diet has affected regulation of pe-
ripheral lipid metabolism, another factor which may be in-
volved in brain insulin resistance. It has been hypothesized 
that peripheral insulin resistance may potentially cause brain 
insulin resistance via a liver-brain axis of neurodegeneration 
as a result of the trafficking of toxic lipids such as ceramides 
across the blood brain barrier (BBB) [36]. 
Further evidence that obesity-induced insulin resistance 
may be a risk factor for AD onset and development derives 
from analysis of a specific array in which genes that are de-
regulated in this state were identified. Changes in levels of 
expression of genes involved in inflammation, innate immu-
nity, insulin and adipokine signaling were detected. The 
highest differences in the profile of expression relative to 
controls were obtained for some of the genes involved in 
inflammation (up-regulated) and adipocytokine signaling 
(down-regulated), mechanisms present both in obesity and 
AD. Inflammation is part of the body’s mechanism of de-
fense against many challenges, and similar inflammatory 
processes are thought to occur in the brain and peripheral 
tissues [45, 46]. The presence of inflammatory markers such 
as cytokines/ chemokines and adipokines has been found in 
the AD brain and has been correlated with changes in the 
permeability of the BBB [47]. Generally, cytokines increase 
activity and expression of secretases, contributing to Aβ 
deposition and pathogenic changes in AD [48]. In particular, 
interferon γ, which produces pleiotropic effects in the brain, 
has been found to increase microglial activation and amyloid 
plaque formation in experimental models [49]. Thus, we 
cannot exclude that increased APP expression, processing 
and Aβ production could be correlated with the inflamma-
tory changes induced by the high fat diet.  
Leptin, adiponectin and resistin messengers are present in 
the brain, and their expression is dysregulated in our mouse 
model of diet-induced obesity. This modulation of adipocy-
tokine messengers suggests that their presence in the brain is 
not exclusively related to peripheral production, and we can-
not exclude a specific role in the central nervous system. 
Adipose tissue produces and releases into the systemic circu-
lation adipocytokines which have metabolic, endocrine and 
anti-inflammatory functions. They can cross the BBB, and 
can therefore exert a neuroprotective role on cognition-
related structures [50]. Consequently, dysfunction of adipo-
cytokines related to obesity may increase the risk of AD. 
Leptin, beside its physiological action, shows beneficial ef-
fects on memory and consequent cognitive improvement 
when directly administrated to the hippocampal region [51]. 
In rodents, leptin plays a role in APP metabolism, by modu-
lating secretase activity, Aβ peptide formation and clearance 
[52]. Leptin also seems to promote deactivation of GSK3β 
[53], and reduced plasma levels of leptin have been associ-
ated with an increased risk of AD development [54]. In 
agreement with this result, we found reduced expression of 
leptin, activated GSK3β and phosphorylated Tau in the 
brains of HFD fed mice. Adiponectin is significantly down-
regulated in the brain of HFD fed mice where probably it is 
less able to exert its pro- anti-inflammatory action [55]. Two 
adiponectin receptors are present in hippocampal neurons, 
AdipoR1-2, and their neuroprotective role is mediated by 
activation of adenosine monophosphate-activated protein 
kinase (AMPK) [56]. Furthermore, adiponectin has been 
demonstrated to reduce Aβ-induced neurotoxicity, likely via 
inhibition of NF-κB. Our results are in agreement with the 
finding of decreased levels of circulating leptin and adi-
ponectin in mild cognitive impairment and AD patients [57]. 
A protective effect of resistin against Aβ-induced neurotox-
icity has been demonstrated in transgenic mice. Resistin at-
tenuates levels of ROS, NO, protein carbonyls, improves 
mitochondrial function and prevents apoptosis by decreasing 
cytochrome c release [58]. Our data suggests that lower lev-
els of adipocytokines may be the cause of the failure of their 
neuroprotective functioning, further evidence for the associa-
tion between obesity and dementia.  
Mitochondrial dysfunction and increased oxidative stress 
are both associated with obesity and AD. Upon high fat diet 
molecules involved in oxidative stress such as phosphory-
lated ERK, i-NOS and H-Oxy are up-regulated with respect 
to the control. This is in agreement with the common knowl-
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edge that inflammatory signals can induce oxidative imbal-
ance and ROS production that can be mediated by stimula-
tion of molecules such as i-NOS, which produces high levels 
of nitricoxide, facilitating the formation of other reactive 
oxygen and nitrogen species [59]. Similarly, markers of mi-
tochondrial dysfunction change their expression in HFD. 
VDAC protein performs several functions in the mitochon-
drion, including maintenance of the mitochondrial perme-
ability transition pore (PTP), regulating its shape and struc-
ture, and in apoptosis signaling [60]. Bcl-2 family members, 
such as Bad, regulate VDAC, leading to apoptogenic release 
of cytochrome c. Recent research has revealed that VDAC1 
is increased in AD postmortem brains and in AD-affected 
brain tissues from AβPP transgenic mice. Additionally, other 
evidence have suggested that a progressive increase in inter-
actions between VDAC1 and Aβ and phosphorylated Tau 
correlate with disease progression [61]. In contrast, a de-
crease of HSP60 levels was detected. This mitochondrial 
chaperonin is a ubiquitous molecule with multiple roles in 
health and disease [62, 63] recently found to be involved in 
insulin resistance [62]. HSP60 appears to be modulated by 
leptin in the hypothalamus of obese and diabetic mice and 
decreased levels of leptin were found in accordance with the 
reduced presence of HSP60 [64]. Decreased levels of leptin, 
as mentioned above, were found correlated with the reduced 
presence of Hsp60. Thus, the neuroprotective role of leptin 
via HSP60 is compromised in our model. An increase in 
mitochondrial fission (Fis1, Drp1) and decrease in fusion 
genes (OPA1, Mfn1) were found in HDF mice. Disordered 
mitochondrial dynamics are a feature of mitochondrial dys-
function and contribute to the pathogenesis of neurodegen-
erative diseases [65, 66]. Fission and fusion regulate funda-
mental cellular processes such as calcium homeostasis, ATP 
generation and ROS production. Unbalanced fusion leads to 
mitochondrial elongation and unbalanced fission leads to 
excessive mitochondrial fragmentation, both of which impair 
mitochondrial function. Moreover, recent studies have dem-
onstrated that obesity and excess energy intake shift the bal-
ance of mitochondrial dynamics, contributing to mitochon-
drial dysfunction and metabolic deterioration all conditions 
leading to insulin resistance [67]. 
CONCLUSION 
This study supports the idea that the metabolic dysfunc-
tion leads to both in peripheral and central tissues, insulin 
resistance, a condition which contributes to inflammation, 
adypokine dysfunction, oxidative stress and mitochondrial 
dysfunction. These mechanisms affect each other through 
up- and down-regulation of specific molecules. In the brain, 
an insulin resistance status, may contribute to an increase in 
Aβ peptide levels and deposits, leading to neurodegeneration 
(Fig. 7). Our findings suggest that preventing the cellular and 
metabolic dysfunctions common to both AD and obesity 
may not only attenuate pathological events in peripheral or-
gans, but also those in the brain. 
 
Fig. (7). A model of mechanisms that contribute and lead to peripheral insulin resistance in obesity and to brain insulin resistance in neu-
rodegeneration. Inflammation, adypokine dysfunction, oxidative stress and mitochondrial dysfunction are interrelated through up- and down-
regulation of specific molecules. 
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